Table 3.

Characteristics and clinical data of 721 NSCLC and 150 SCLC patients of CAPUA study

Variables	NSCLC							SCLC
	Patients		Deaths	MST (months)	Log-rank	HR	95% CI	Patients		Deaths	MST (months)	Log-rank	HR	95% CI
	n	%						n	%
Gender					0.293							0.053
Male	643	89.2	598	9.3		1.00		134	89.3	123	8.3		1.00
Female	78	10.8	68	12.5		0.87	0.68-1.12	16	10.7	14	14.5		0.57	0.32-1.02
Age (years)					0.083							0.041
≤ 68	375	52.0	342	11.3		1.00		79	52.7	69	9.8		1.00
> 68	346	48.0	324	8.2		1.15	0.98-1.34	71	47.3	68	7.6		1.42	1.01-2.00
Smoking Status					0.585							0.025
Never	45	6.3	41	10.5		1.00		7	4.7	6	54.2		1.00
Ever	672	93.7	621	9.5		0.92	0.67-1.26	142	95.3	130	8.4		2.51	1.09-5.75
Former	307	45.8	284	9.4	0.809	0.90	0.65-1.25	59	41.8	54	7.5	0.022	2.88	1.29-6.43
Current	363	54.2	335	9.5		0.93	0.67-1.28	82	58.2	75	9.2		2.24	1.02-4.91
Histological Types					0.608
Squamous cell carcinoma	358	49.6	335	10.9		1.00
Adenocarcinoma	264	36.6	240	10.2		1.05	0.89-1.24
Others	99	13.7	91	7.8		1.12	0.89-1.43
Clinical stages					0.000
I	186	26.1	151	26.1		1.00						0.000
II	58	8.1	51	19.7		1.45	1.05-2.00
III	244	34.3	238	9.6		2.26	1.83-2.79
IV	224	31.5	220	5.2		3.97	3.19-4.94
Limited stage (LS)								78	52.3	69	12.2		1.00
Extend stage (ES)								71	47.7	67	5.8		2.19	1.54-3.11
Surgical Operation					0.000
None	523	72.5	509	7.2		1.00
Yes	198	27.5	157	30.9		0.32	0.27-0.39
Chemo or Radiotherapy					0.469
None	301	41.7	262	6.9		1.00
Yes	420	58.3	412	11.7		1.06	0.90-1.24
Chemotherapy												0.000
None								29	19.3	28	1.6		1.00
Yes								121	80.7	109	9.9		0.41	0.26-0.62
Radiotherapy												0.000
None								74	49.3	71	5.4		1.00
Yes								76	50.7	66	12.1		0.46	0.32-0.64

NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MST: median survival